OncoMatch/Clinical Trials/NCT07051486
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Is NCT07051486 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies SHR-A1811 for recurrent or metastatic cervical cancer.
Treatment: SHR-A1811 — This study is a single-arm, multicenter Phase II clinical trial of SHR-A1811 for injection in patients with HER2-expressing recurrent or metastatic cervical cancer who have failed prior systemic therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cervical Cancer
Biomarker criteria
Required: HER2 (ERBB2) expression (HER2-expressing)
HER2-Expressing Recurrent/Metastatic Cervical Cancer
Disease stage
Metastatic disease required
Demographics
Lab requirements
Blood counts
Normal function of important organs
Kidney function
Normal function of important organs
Liver function
Normal function of important organs
Cardiac function
Normal function of important organs
Normal function of important organs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07051486 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ERBB2?
Yes, ERBB2 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages